Extending the Nonsurgical Management of Fibroid-Associated Heavy Menstrual Bleeding

In: Journal watch · 2020 · vol. 2020 · doi:10.1056/nejm-jw.na51542 · W3025296970
article OA: closed CC0
View on OpenAlex View at publisher
AI-generated summary by gemini-2.5-flash-lite, 2026-08-01

Elagolix, an oral GnRH antagonist, effectively reduced heavy menstrual bleeding in patients with uterine fibroids, demonstrating its potential for nonsurgical management.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist approved for endometriosis-associated pelvic pain, represents an option for

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK